Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

BACKGROUND: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. METHODS: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349178/
https://ncbi.nlm.nih.gov/pubmed/22510747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados